A small medical device company engaged Magnolia Market Access to strengthen its evidence strategy and value messaging for an innovative oncology device. Despite strong clinical results, the company needed to address evidence gaps and ensure its value story resonated with payers and providers.
As states expand PDAB authority to set Upper Payment Limits (UPLs) on high-cost therapies, Magnolia Market Access surveyed physicians in Colorado, Maryland, Oregon, and Washington to understand how these policies may affect prescribing decisions, patient care, and clinical operations.
This issue brief provides insights into how 340B savings are being redirected by covered entities—particularly DSH hospitals—toward financial investments instead of patient care, underscoring the urgency of policy changes to realign the program with its mission.
In the June 2025 Navigating Market Access with Magnolia webinar, experts from across the market access ecosystem came together to examine the forces reshaping how manufacturers plan for pricing, reimbursement, and access.
In this featured presentation from the 2025 Evidence 360 Summit, Magnolia Market Access’s Beni Turner explores how RWE can be strategically integrated across the product lifecycle to drive more effective pricing and access outcomes.
On May 12, 2025, President Trump signed an executive order with the potential to significantly change the U.S. drug pricing and distribution system. Here is what we know about the Administration’s new Most Favored Nation (MFN) policy:
At Magnolia Market Access, we see frailty as a key variable in evidence generation and access strategy. Ahead of ISPOR 2025, we sat down with Mike Murphy to discuss Magnolia’s latest research using administrative claims data to evaluate frailty indices.
Formulary coverage assessments are a critical component of successful market access strategies. As payer policies grow more complex and cost-containment tactics become more aggressive, pharmaceutical manufacturers must stay ahead of how coverage decisions impact product access, prescriber behavior, and ultimately, patient outcomes.
With the recent release of the 2025 Medicare plan enrollment data, pharma manufacturers must address significant shifts in the Part D prescription drug plan market, that could impact market access, formulary positioning, and patient affordability. We spoke with Parker Edman about the trends, challenges, and what manufacturers should prioritize to stay ahead.
The issue brief explores the PORTAL toolkit for Prescription Drug Affordability Boards (PDABs), highlighting key concerns and potential impacts on drug pricing, patient access, and policy implementation.